TITLE

Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

AUTHOR(S)
Raveendran, Ganesh; Ting, Henry H.; Best, Patricia J.; Holmes, Jr., David R.; Lennon, Ryan J.; Singh, Mandeep; Bell, Malcolm R.; Long, Kirsten Hall; Rihal, Charanjit S.
PUB. DATE
February 2007
SOURCE
Mayo Clinic Proceedings;Feb2007, Vol. 82 Issue 2, p196
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To compare outcomes among patients receiving eptifibatide or abciximab during primary percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) with ST elevation or new left bundle branch block. PATIENTS AND METHODS: From January 1999 through January 2004, 576 patients underwent primary PCI and received adjunctive glycoprotein llb/llla receptor antagonists. Propensity scores were used to adjust for baseline differences between groups. Logistic regression and Cox proportional hazards were used to model the association between choice of glycoprotein llb/Illa receptor antagonist and adverse events. RESULTS: Abciximab was given to 327 patients (57%) and eptifibatide to 249 (43%). Observed rates of ln-hospital death or Ml did not differ between groups (eptifibatide, 6%; abciximab,5%; P=.95). This result persisted with adjustment for various patient characteristics (adjusted odds ratio, 1.03; 95% confidence interval, 0.40-2.65; P=.95). Kaplan-Meier estimated rates of death, Ml, or target vessel revascularization at 1-year follow-up were 20.9% with eptifibatide and 22.3% with abciximab. The adjusted hazard ratio for the composite end point during a median follow-up of 12 months was 1.36 (95% confidence interval, 0.89-2.07; P=.16). CONCLUSION: In this observational analysis, outcomes were similar with use of either abciximab or eptifibatide among patients undergoing primary PCI for acute MI. Additional comparative research is warranted to confirm these results.
ACCESSION #
24013417

 

Related Articles

  • Treatment delays in ST elevation mvocardial infarction. Terkelsen, Christian Julh; Lassen, Jens Flensted // BMJ: British Medical Journal (International Edition);2/23/2008, Vol. 336 Issue 7641, p401 

    The authors reflect on treatment delays in ST elevation myocardial infarction. They suggest that the delays can be reduced by prehospital diagnosis and the direct transfer to high volume catheterisation laboratories. They argue that setting up large volume treatment and intervention centers may...

  • Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention: A Randomized Controlled Trial. Kastrati, Adnan; Mehilli, Julinda; Schlotterbeck, Klaus; Dotzer, Franz; Dirschinger, Josef; Schmitt, Claus; Nekolla, Stephan G.; Seyfarth, Melchior; Martinoff, Stefan; Markwardt, Christina; Clermont, Günther; Gerbig, Hans-Wilhelm; Leiss, Johannes; Schwaiger, Markus; Schömig, Albert // JAMA: Journal of the American Medical Association;2/25/2004, Vol. 291 Issue 8, p947 

    Context: The optimal pharmacological strategy for bridging the delay between admission and performance of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) is not known. Objective: To assess whether early administration of reteplase plus abciximab...

  • Fast, aggressive treatment for myocardial infarction urged. Mitka, Mike; Mitka, M // JAMA: Journal of the American Medical Association;12/20/2000, Vol. 284 Issue 23, p2985 

    Presents results from trials regarding myocardial infarction announced at the American Heart Association's annual scientific sessions in November 2000. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial and the use of atorvastatin in treatment; Treat Angina with...

  • Treatment of Right Ventricular Infarction. Movahed, Assad // American Family Physician;10/15/1999, Vol. 60 Issue 6, p1640 

    Editorial. Discusses the treatment for right ventricular infarction. Occurrence of right ventricular infarction; Description of right ventricular infarction; Diagnosis of right ventricular infarction.

  • Heart Attack Treatment.  // HealthFacts;Feb2000, Vol. 25 Issue 2, p5 

    Provides information on the treatment for heart attack.

  • Reperfusion Therapy for Acute Myocardial Infarction: Which Strategy for Which Patient? Boersma, E.; Steyerberg, E.W.; van der Vlugt, M.J.; Simoons, M.L. // Drugs;Jul1998, Vol. 56 Issue 1, p31 

    Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been developed, which differ in terms of effectiveness, complexity and costs. Reperfusion resources are often restricted by budgetary or logistical circumstances. To arrive at an equitable distribution of treatment...

  • Acute Coronary Syndrome: A Concise Summary for the Non-cardiologist. McFeely, James E. // Critical Care Alert;May2009, Vol. 17 Issue 2, p14 

    The article offers information on the management of the acute coronary syndrome of ST-elevation myocardial infarction (STEMI).

  • Code STEMI: implementation of a city-wide program for rapid assessment and management of myocardial infarction. Le May, Michel // CMAJ: Canadian Medical Association Journal;10/13/2009, Vol. 181 Issue 8, pE136 

    The article presents an essay, in which the author offers information on his research work on rapid management of myocardial infarction. The author informs that a city-wide program, called Code STEMI, was developed in Ottawa, Ontario that provided percutaneous coronary intervention to myocardial...

  • A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction. Lamotte, Mark; Annemans, Lieven; Kawalec, Pawel; Zoellner, York // PharmacoEconomics;2006, Vol. 24 Issue 8, p783 

    Background: Patients who survive an acute myocardial infarction (MI) are at an Abstract increased risk of subsequent major cardiovascular events and (often sudden) cardiac death. The use of highly concentrated and purified omega-3 polyunsaturated fatty acids (n-3 PUFAs), in addition to standard...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics